Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Combined Inhibition of JAK2 and mTOR Signaling Results in Enhanced Efficacy in in-Vitro and Preclinical Mouse Models of JAK2V617F-Driven Myeloproliferative Disease

Alessandro M. Vannucchi, MD, Niccolò Bartalucci, PhD, Costanza Bogani, PhD, Serena Martinelli, BiSci, Lorenzo Tozzi, PhD, Alberto Bosi, MD, Jean-Luc Villeval, PhD

Blood (2012) 120 (21): 708.

https://doi.org/10.1182/blood.V120.21.708.708

Published: 2012

Journal Articles

Inhibitors of PI3K/Akt and/or mTOR Inhibit the Growth of Cells of Myeloproliferative Neoplasms and Synergize with JAK2 Inhibitor and Interferon,

Alessandro M. Vannucchi, MD, Costanza Bogani, PhD, Niccolò Bartalucci, BiSc, Lorenzo Tozzi, BiSci, Serena Martinelli, BiSci, Paola Guglielmelli, MD, PhD, Chiara Paoli, BiSci, Lisa Pieri, MD, Alberto Bosi, MD

Blood (2011) 118 (21): 3835.

https://doi.org/10.1182/blood.V118.21.3835.3835

Published: 2011

Journal Articles

Characterization of Targets of Plitidepsin In JAK2 V617F-Mutated Cells From Myeloproliferative Neoplasms

Paola Guglielmelli, MD, Costanza Bogani, PhD, Niccolò Bartalucci, BiSc, Lisa Pieri, MD, Alessandro Pancrazzi, BiSc, Alberto Bosi, MD, Andrea Bisognin, MD, Miguel Aracil, Stefania Bortoluzzi, PhD, Alessandro M. Vannucchi, MD

Blood (2010) 116 (21): 4093.

https://doi.org/10.1182/blood.V116.21.4093.4093

Published: 2010

Journal Articles

Plitidepsin Inhibits the Growth of Cells Harboring JAK2V617F Mutation.

Costanza Bogani, PhD, Paola Guglielmelli, MD, Niccolò Bartalucci, BSc, Miguel Aracil, MD, Maria Fe Paz, PhD, Alberto Bosi, MD, Alessandro M. Vannucchi, MD

Blood (2009) 114 (22): 3907.

https://doi.org/10.1182/blood.V114.22.3907.3907

Published: 2009

Journal Articles

The mTOR Inhibitor, RAD001, Inhibits the Growth of Cells From Patients with Myeloproliferative Neoplasms.

Alessandro M. Vannucchi, MD, Costanza Bogani, PhD, Niccolò Bartalucci, BSc, Paola Guglielmelli, MD, Lorenzo Tozzi, BSc, Elisabetta Antonioli, MD, Lisa Pieri, MD, Alberto Bosi, MD

Blood (2009) 114 (22): 2914.

https://doi.org/10.1182/blood.V114.22.2914.2914

Published: 2009

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Combined Inhibition of JAK2 and mTOR Signaling Results in Enhanced Efficacy in in-Vitro and Preclinical Mouse Models of JAK2V617F-Driven Myeloproliferative Disease

Inhibitors of PI3K/Akt and/or mTOR Inhibit the Growth of Cells of Myeloproliferative Neoplasms and Synergize with JAK2 Inhibitor and Interferon,

Characterization of Targets of Plitidepsin In JAK2 V617F-Mutated Cells From Myeloproliferative Neoplasms

Plitidepsin Inhibits the Growth of Cells Harboring JAK2V617F Mutation.

The mTOR Inhibitor, RAD001, Inhibits the Growth of Cells From Patients with Myeloproliferative Neoplasms.

Email alerts

ASH Publications

American Society of Hematology

Update search

Combined Inhibition of JAK2 and mTOR Signaling Results in Enhanced Efficacy in in-Vitro and Preclinical Mouse Models of JAK2V617F-Driven Myeloproliferative Disease

Inhibitors of PI3K/Akt and/or mTOR Inhibit the Growth of Cells of Myeloproliferative Neoplasms and Synergize with JAK2 Inhibitor and Interferon,

Characterization of Targets of Plitidepsin In JAK2 V617F-Mutated Cells From Myeloproliferative Neoplasms

Plitidepsin Inhibits the Growth of Cells Harboring JAK2V617F Mutation.

The mTOR Inhibitor, RAD001, Inhibits the Growth of Cells From Patients with Myeloproliferative Neoplasms.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only